Bone Marrow Grafting for Leukemia and Lymphoma
December 17, 2025 updated by: Stanford University
The purpose of this study is to obtain tissue samples for ongoing studies regarding transplant outcomes and complications.
Study Overview
Status
Enrolling by invitation
Conditions
Intervention / Treatment
Detailed Description
The purpose of this study is to acquire critical tissue and biological samples that can be evaluated to elucidate underlying mechanisms of disease control, transplant related complications and overall outcomes
Study Type
Observational
Enrollment (Estimated)
9999
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Stanford, California, United States, 94305
- Stanford University School of Medicine
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
All hematopoietic cell transplant recipients and donors who agree to participate
Description
Inclusion Criteria:- All hematopoietic cell transplant recipients and donors who agree to participate
Exclusion Criteria:- Subject does not agree to participate
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Graft recipients and donors
|
Tissue samples include blood draws for the donor and recipient.
A bone marrow sample may be obtained from the recipient.
If the recipient undergoes a tissue biopsy for clinical reasons, a small fraction may be removed for research purposes.
A small fraction of the donor graft may be removed at the time of collection for research.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Identify and characterize proteins and genes that may contribute to the development and progression of cancer.
Time Frame: blood sample is collected prior transplant, periodically during the first three months and then indefinately at follow up
|
blood sample is collected prior transplant, periodically during the first three months and then indefinately at follow up
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Robert S Negrin, Stanford University
- Principal Investigator: David Miklos, Stanford University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 1988
Primary Completion (Estimated)
December 1, 2069
Study Completion (Estimated)
December 1, 2069
Study Registration Dates
First Submitted
September 13, 2005
First Submitted That Met QC Criteria
September 13, 2005
First Posted (Estimated)
September 16, 2005
Study Record Updates
Last Update Posted (Estimated)
December 18, 2025
Last Update Submitted That Met QC Criteria
December 17, 2025
Last Verified
December 1, 2025
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB-08903
- P01CA049605 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.